Latest & greatest articles for measles

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on measles or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on measles and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for measles

81. The measles-mumps-rubella vaccine (MMR) and autism

The measles-mumps-rubella vaccine (MMR) and autism The measles-mumps-rubella vaccine (MMR) and autism The measles-mumps-rubella vaccine (MMR) and autism Higgins S Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Higgins S. The measles-mumps-rubella vaccine (MMR) and autism. Clayton, Victoria: Centre for Clinical Effectiveness (CCE) 2003: 14 Authors' objectives (...) This aim of this critical appraisal was to assess whether the combined measles-mumps-rubella vaccine (MMR) given according to the Department of Health's immunisation schedule increase the child's risk of developing autism. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Autistic Disorder; Measles-Mumps-Rubella Vaccine /adverse effects Language Published English Country of organisation Australia Address for correspondence Monash Institute of Health Services Research, Block E

2003 Health Technology Assessment (HTA) Database.

82. Association of autistic spectrum disorder and the measles, mumps, and rubella vaccine: a systematic review of current epidemiological evidence

Association of autistic spectrum disorder and the measles, mumps, and rubella vaccine: a systematic review of current epidemiological evidence Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2003 DARE.

83. A population-based study of measles, mumps, and rubella vaccination and autism. (Abstract)

A population-based study of measles, mumps, and rubella vaccination and autism. It has been suggested that vaccination against measles, mumps, and rubella (MMR) is a cause of autism.We conducted a retrospective cohort study of all children born in Denmark from January 1991 through December 1998. The cohort was selected on the basis of data from the Danish Civil Registration System, which assigns a unique identification number to every live-born infant and new resident in Denmark. MMR

2002 NEJM

84. First 5 years of measles elimination in southern Africa: 1996-2000. (Abstract)

First 5 years of measles elimination in southern Africa: 1996-2000. Measles is the leading cause of vaccine-preventable death in Africa. Regional measles elimination is considered feasible using current vaccines and a series of WHO-recommended strategies. We aimed to interrupt transmission of measles, and to use case-based surveillance to show the effect of such interruption.In southern Africa from 1996, seven countries with a total population of approximately 70 million and with relatively (...) high routine vaccination coverage implemented measles elimination strategies. In addition to routine measles immunisation at 9 months of age, these included nationwide catch-up campaigns among children aged 9 months to 14 years, then follow-up campaigns every 3-4 years among children aged 9-59 months, and the establishment of case-based measles surveillance with serological diagnostic confirmation.Nearly 24 million children aged 9 months to 14 years were vaccinated, with overall vaccination

2002 Lancet

85. Measles, mumps, and rubella vaccination and bowel problems or developmental regression in children with autism: population study. Full Text available with Trip Pro

Measles, mumps, and rubella vaccination and bowel problems or developmental regression in children with autism: population study. To investigate whether measles, mumps, and rubella (MMR) vaccination is associated with bowel problems and developmental regression in children with autism, looking for evidence of a "new variant" form of autism.Population study with case note review linked to independently recorded vaccine data.Five health districts in north east London.278 children with core autism

2002 BMJ

86. Effect of vitamin A supplementation on measles-specific antibody levels in Guinea-Bissau. (Abstract)

Effect of vitamin A supplementation on measles-specific antibody levels in Guinea-Bissau. We have previously reported that vitamin A supplementation with measles vaccine at age 9 months increases measles-specific antibody concentrations in children at age 18 months compared with placebo. We examined these children when they reached age 6-8 years. Fewer vitamin A-supplemented children had non-protective antibody concentrations (p=0.0095); among children with protective antibody levels, vitamin (...) A-supplemented children tended to have higher geometric mean antibody titres (p=0.09). Thus, simultaneous administration of vitamin A and measles vaccine at age 9 months had a long-term effect on measles-specific antibody levels and may contribute to improved measles control in less-developed countries.

2002 Lancet Controlled trial quality: uncertain

87. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. (Abstract)

The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. The administration of the diphtheria and tetanus toxoids and whole-cell pertussis (DTP) vaccine and measles, mumps, and rubella (MMR) vaccine has been associated with adverse neurologic events, including seizures. We studied the relation between these vaccinations and the risk of a first seizure, subsequent seizures, and neurodevelopmental disability in children.This cohort study was conducted

2001 NEJM

88. Vitamin A for treating measles in children. (Abstract)

Vitamin A for treating measles in children. Measles is a leading cause of childhood morbidity and mortality. Vitamin A deficiency is a recognised risk factor for severe measles. The World Health Organization (WHO) recommends administration of an oral dose of 200,000 IU (or 100,000 IU in infants) of vitamin A per day for two days to children with measles in areas where vitamin A deficiency may be present.The purpose of this review is to determine whether vitamin A when commenced after measles (...) has been diagnosed, is beneficial in preventing mortality, pneumonia and other complications in children.MEDLINE and the Cochrane Library, Issue 4, 1999 were searched.Only randomized controlled trials in which children with measles were given vitamin A or placebo along with standard treatment were considered.Studies were assessed independently by two reviewers. The analysis of dichotomous outcomes was done using the StatExact software package. Sub-group analyses were done for dose, formulation

2001 Cochrane

89. Evaluating the benefits of increasing measles immunization rates

Evaluating the benefits of increasing measles immunization rates Evaluating the benefits of increasing measles immunization rates Evaluating the benefits of increasing measles immunization rates Zwanziger J, Szilagyi P G, Kaul P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability (...) of the study and the conclusions drawn. Health technology The study evaluated the effects of increasing measles immunisation rates beyond its baseline value in pre-school children. The comparator was the "do nothing" alternative. Type of intervention Primary prevention (vaccination). Economic study type Cost-utility analysis. Study population The study population comprised pre-school children in urban areas. Setting The setting was the community. The economic study was carried out in the USA. Dates

2001 NHS Economic Evaluation Database.

90. Antibiotics for preventing pneumonia in children with measles. (Abstract)

Antibiotics for preventing pneumonia in children with measles. Measles causes more than a million deaths a year, of which most are children under five years of age who die from pneumonia.The objective of this review was to assess the effects of antibiotics given to children with measles on reducing pneumonia or mortality, and to assess whether antibiotics should be given to all children with measles in communities with a high fatality rate.We searched MEDLINE (1966 - 1999), EMBASE (1980-1999 (...) , the incidence of pneumonia in the control group was similar to that in the antibiotic prophylaxis group; in the other two studies, the incidence of pneumonia was unusually high in the control group so these children had a higher complication rate than the antibiotic group. Four of the 764 children given antibiotics died compared with one of the 637 controls.The quality of the trials reviewed was poor, and they provide very weak evidence for giving antibiotics to all children with measles. Available evidence

2000 Cochrane

91. Response to different measles vaccine strains given by aerosol and subcutaneous routes to schoolchildren: a randomised trial. (Abstract)

Response to different measles vaccine strains given by aerosol and subcutaneous routes to schoolchildren: a randomised trial. More than one dose of measles vaccine is necessary for the sustained control of measles. The aerosol route is thought to be more immunogenic for booster doses than traditional subcutaneous injections, so we did a randomised comparative trial of aerosol and subcutaneous measles vaccines in South African schoolchildren.4327 schoolchildren (aged 5-14 years), assigned (...) by block randomisation of classrooms, received standard titre doses of either Schwarz or Edmonston-Zagreb measles vaccines subcutaneously or by aerosol. Blood samples for antibody assay were collected before vaccination, at 1 month, and 1 year after vaccination. The main endpoints (antibody titres at 1 month and 1 year) were compared between groups.992 children had antibody titre data available for all timepoints. 14 (3.6%) of 385 children who received Edmonston-Zagreb vaccine by aerosol were

2000 Lancet Controlled trial quality: uncertain

92. [Raising the immunization rate in medical students against measles, mumps and rubella at the University of Berne]

[Raising the immunization rate in medical students against measles, mumps and rubella at the University of Berne] Die Erhohung der Immunitatsrate von Medizinstudentinnen und studenten gegen Masern, Mumps und Roteln an der Universitat Bern [Raising the immunization rate in medical students against measles, mumps and rubella at the University of Berne] Die Erhohung der Immunitatsrate von Medizinstudentinnen und studenten gegen Masern, Mumps und Roteln an der Universitat Bern [Raising (...) the immunization rate in medical students against measles, mumps and rubella at the University of Berne] Germann D, Matter L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Vaccination of medical students against measles, mumps and rubella

1999 NHS Economic Evaluation Database.

93. Cost-effectiveness of measles outbreak intervention strategies

Cost-effectiveness of measles outbreak intervention strategies Cost-effectiveness of measles outbreak intervention strategies Cost-effectiveness of measles outbreak intervention strategies Shiell A, Jorm L R, Carruthers R, Fitzsimmons G J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment (...) on the reliability of the study and the conclusions drawn. Health technology Alternative measles outbreak intervention strategies in schools. Type of intervention Primary prevention. Economic study type Cost-effectiveness analysis. Study population The study population was a single, hypothetical, primary school population of 500 students (aged 5 to 10 years) and their younger siblings. Setting The setting was community, primary care, and hospital. The economic study was carried out in western Sydney, Australia

1998 NHS Economic Evaluation Database.

94. Randomised, double blind, placebo controlled clinical trial of efficacy of vitamin A treatment in non-measles childhood pneumonia. Full Text available with Trip Pro

Randomised, double blind, placebo controlled clinical trial of efficacy of vitamin A treatment in non-measles childhood pneumonia. To evaluate the impact on clinical recovery and severity of the addition of large doses of vitamin A to the standard treatment for childhood pneumonia.A randomised, double blind, placebo controlled trial.Study children were recruited at a public hospital in Recife, north east Brazil, an area of marginal vitamin A deficiency.472 children aged 6 to 59 months

1997 BMJ Controlled trial quality: predicted high

95. Randomised trial of effect of vitamin A supplementation on antibody response to measles vaccine in Guinea-Bissau, west Africa. (Abstract)

Randomised trial of effect of vitamin A supplementation on antibody response to measles vaccine in Guinea-Bissau, west Africa. WHO has recommended vitamin A supplementation for children aged 6 months or older in developing countries at the same time as immunisation. One study has reported significantly lower seroconversion ratios among children who have received vitamin A supplements with measles vaccine at age 6 months. The aim of our study was to assess the effect of vitamin A supplementation (...) on antibody response to measles vaccination at age 9 months, which is the more common age for immunisation in developing countries.In an urban community in Guinea-Bissau, we did a randomised, double-blind, placebo-controlled study of the effect of simultaneous vaccination and vitamin A supplementation in 462 children who received either a two-dose schedule of measles vaccine at the ages of 6 months and 9 months (150 infants) or one dose of measles vaccine at age 9 months (312 infants). Children were

1997 Lancet Controlled trial quality: predicted high

96. Meta-analysis of trials of prophylactic antibiotics for children with measles: inadequate evidence

Meta-analysis of trials of prophylactic antibiotics for children with measles: inadequate evidence Meta-analysis of trials of prophylactic antibiotics for children with measles: inadequate evidence Meta-analysis of trials of prophylactic antibiotics for children with measles: inadequate evidence Shann F Authors' objectives To assess whether prophylactic antibiotics should be given to all children with measles in communities with a high (more than 1%) fatality rate. Searching MEDLINE (...) was searched from 1966 to 1995 using the terms 'measles' plus either 'antibiotic', 'penicillin', 'sulphonamide', 'prospective studies' or 'RCT'. Additional studies were obtained by examining results of previous handsearches of studies of pneumonia in children, in all the journals in the University library from 1935 to 1946. Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs) comparing routine antibiotic prophylaxis with no antibiotic or with selective

1997 DARE.

97. Alternative routes of measles immunization: a review

Alternative routes of measles immunization: a review Alternative routes of measles immunization: a review Alternative routes of measles immunization: a review Cutts F T, Clements C J, Bennett J V Authors' objectives To evaluate the potential for non-percutaneous routes of vaccine administration for measles to improve control. Searching The authors state that a literature search was conducted but do not report the names of databases, dates searched or keywords used in the search. Early studies (...) (drops in the eye), oral (drops on sugar, spray on back of oropharynx, or cotton swab), aerosol (nebuliser with reconstituted vaccine placed in a container of crushed ice and attached to a compressor, with dose assumed of 0.145 ml per 30 seconds) and intranasal (swab in anterior nares, drops or bolus instillation in the anterior nares, or large particle spray) administrations of measles vaccine. Participants included in the review Participants were children who were grouped into categories of: 1

1997 DARE.

98. Secondary failure rates of measles vaccines: a metaanalysis of published studies

Secondary failure rates of measles vaccines: a metaanalysis of published studies Secondary failure rates of measles vaccines: a metaanalysis of published studies Secondary failure rates of measles vaccines: a metaanalysis of published studies Anders J F, Jacobson R M, Poland G A, Jacobsen S J, Wollan P C Authors' objectives To estimate the rate of clinical measles after vaccine-induced seroconversion of measles vaccines using a meta-analysis. Searching The computerised National Library (...) in the review Measles vaccine containing either live or killed virus. Participants included in the review Healthy individuals receiving a measles-containing vaccine over the age of 12 months were included. Outcomes assessed in the review Secondary failures of vaccination. Primary failures are failures of the vaccine to produce measurable specific antibodies after immunisation. Secondary failures are the manifestation of the disease in an individual previously shown to have measurable specific antibodies

1996 DARE.

99. An evaluation of measles revaccination among school-entry-aged children

An evaluation of measles revaccination among school-entry-aged children An evaluation of measles revaccination among school-entry-aged children An evaluation of measles revaccination among school-entry-aged children Watson J C, Pearson J A, Markowitz L E, Baughman A L, Erdman D D, Bellini W J, Baron R C, Fleming D W Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two dose measles vaccination schedule. Type of intervention Primary prevention. Economic study type Cost-effectiveness analysis. Study population Children aged 4-6 years who had received one dose of measles vaccine at age 15-17 months and who had been enrolled at the time in the study HMO (see below) and still were at the time of the study. These children had

1996 NHS Economic Evaluation Database.

100. Reduced seroconversion to measles in infants given vitamin A with measles vaccination. (Abstract)

Reduced seroconversion to measles in infants given vitamin A with measles vaccination. Administration of 100,000 IU vitamin A at the time of measles immunisation is currently recommended for infants in developing countries. However, the safety and value of giving vitamin A, a potent immune enhancer, with live measles virus vaccines are unknown. We conducted a randomised, double-blind, placebo-controlled clinical trial in Indonesia to evaluate the effect of simultaneous vitamin A supplementation (...) on the immune response to measles immunisation at six months of age. 336 infants received either vitamin A (100,000 IU) or placebo when immunised with standard-titre Schwarz measles vaccine. 82% of infants seroconverted to measles. In a multiple logistic regression model adjusting for maternal antibody titres, vitamin A supplementation was associated with a lower likelihood of seroconversion to measles (odds ratio 0.40, 95% CI 0.19-0.88), and girls were less likely to seroconvert than boys (0.34, 0.15-0.76

1995 Lancet Controlled trial quality: predicted high